Unlocking the Blood–Brain Barrier: A Role for RMP-7 in Brain Tumor Therapy

1996 ◽  
Vol 141 (2) ◽  
pp. 214-224 ◽  
Author(s):  
Peter J. Elliott ◽  
Neil J. Hayward ◽  
Michael R. Huff ◽  
Tricia L. Nagle ◽  
Keith L. Black ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Blood Brain Barrier ◽  
Tumor Therapy ◽  
Brain Barrier ◽  
Blood Brain ◽  
Brain Tumor Therapy

Permeability of PEGylated Immunoarsonoliposomes Through In Vitro Blood Brain Barrier-Medulloblastoma Co-culture Models for Brain Tumor Therapy

2014 ◽  
Vol 32 (3) ◽  
pp. 1072-1083 ◽  
Author(s):  
Abdulghani Al-Shehri ◽  
Marco E. Favretto ◽  
Panayiotis V. Ioannou ◽  
Ignacio A. Romero ◽  
Pierre-Olivier Couraud ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Blood Brain Barrier ◽  
Tumor Therapy ◽  
Brain Barrier ◽  
Blood Brain ◽  
Culture Models ◽  
Brain Tumor Therapy

scholarly journals Remodeling the blood–brain barrier microenvironment by natural products for brain tumor therapy

2017 ◽  
Vol 7 (5) ◽  
pp. 541-553 ◽  
Author(s):  
Xiao Zhao ◽  
Rujing Chen ◽  
Mei Liu ◽  
Jianfang Feng ◽  
Jun Chen ◽  
...  
Keyword(s):  
Natural Products ◽  
Brain Tumor ◽  
Blood Brain Barrier ◽  
Tumor Therapy ◽  
Brain Barrier ◽  
Blood Brain ◽  
Brain Tumor Therapy

scholarly journals Examination of blood–brain barrier (BBB) integrity in a mouse brain tumor model

2012 ◽  
Vol 111 (2) ◽  
pp. 133-143 ◽  
Author(s):  
Ngoc H. On ◽  
Ryan Mitchell ◽  
Sanjot D. Savant ◽  
Corbin. J. Bachmeier ◽  
Grant M. Hatch ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Blood Brain Barrier ◽  
Mouse Brain ◽  
Tumor Model ◽  
Brain Barrier ◽  
Blood Brain ◽  
Brain Tumor Model

Strategies to Modulate the Blood-Brain Barrier for Directed Brain Tumor Targeting

2020 ◽  
pp. 79-108
Author(s):  
Paula Schiapparelli ◽  
Montserrat Lara-Velazquez ◽  
Rawan Al-kharboosh ◽  
Hao Su ◽  
Honggang Cui ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Blood Brain Barrier ◽  
Tumor Targeting ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals 64. AN ENT2-DEPENDENT, CELL-PENETRATING, AND DNA-DAMAGING LUPUS AUTOANTIBODY CROSSES THE BLOOD-BRAIN BARRIER TO TARGET BRAIN TUMORS

2020 ◽  
Vol 2 (Supplement_2) ◽  
pp. ii13-ii13
Author(s):  
Zahra Rattray ◽  
Gang Deng ◽  
Shenqi Zhang ◽  
Anupama Shirali ◽  
Christopher May ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Blood Brain Barrier ◽  
Tumor Therapy ◽  
Brain Barrier ◽  
Live Cells ◽  
Nucleoside Transporter ◽  
Blood Brain ◽  
Cell Penetrating ◽  
Dependent Cell

Abstract The blood-brain barrier (BBB) limits conventional antibody-based approaches to brain tumors. ENT2, an equilibrative nucleoside transporter, facilitates penetration of autoantibodies into live cells and is expressed in the BBB. PAT-DX1 (also known as Deoxymab-1 or DX1) is an ENT2-dependent, cell-penetrating, and DNA-damaging lupus autoantibody that is synthetically lethal to cancer cells with defects in the DNA damage response. PTEN loss renders sensitivity to DX1 and is common in primary and metastatic brain tumors. We show that DX1 is toxic to spheroids derived from primary PTEN-deficient glioblastoma (GBM), and crosses the BBB to suppress the growth of orthotopic GBM and breast cancer brain metastases. Mechanistically, we find the ENT2 inhibitor dipyridamole blocks DX1 penetration into brain endothelial cells and transport across the BBB in vitro and in vivo, consistent with ENT2-mediated uptake of DX1 into brain tumors. Autoantibodies that hijack nucleoside transporters to cross cell membranes may open new frontiers in brain tumor therapy.

Sign in / Sign up

Export Citation Format

Share Document